Karatage Shane O’Callaghan Appointment: IMC Veteran Joins Crypto Hedge Fund
London-based Karatage appoints IMC veteran Shane O’Callaghan as senior partner to lead institutional strategy in the digital asset market.
Stepping away from the safety of elite institutional roles to build something aggressive. London-based proprietary hedge fund Karatage has appointed IMC Trading veteran Shane O’Callaghan as senior partner and head of institutional strategy.
Karatage Shane O’Callaghan Appointment Signals Institutional Expansion
O’Callaghan joins the firm after serving as Global Head of Institutional Partnerships at the Dutch market maker IMC. His extensive track record includes leadership roles at Portofino Technologies and the former crypto lender BlockFi. Karatage CEO Marius Barnett noted that Shane's move represents a rare opportunity to execute at a higher level and raise the standard for digital asset management.
Thematic Investing in the Blockchain Economy
Founded in 2017, Karatage has remained active through multiple market cycles. The fund typically combines liquid token investments with long-term bets on blockchain infrastructure. According to O’Callaghan, the firm's blend of proprietary capital and technical depth is exactly what the institutional market requires in 2026 to navigate the evolving financial landscape.
This content is AI-generated based on source articles. While we strive for accuracy, errors may occur. We recommend verifying with the original source.
Related Articles
US Crypto Bill Senate Votes face a standstill as Democrats demand fundamental changes. Explore the impact of this legislative deadlock on the 2026 digital asset market.
Kinexys brings regulated digital cash to the Canton Network, marking a major milestone for Kinexys Canton Network interoperability in global finance.
Explore the latest Crypto Market Movements 2026. Tokens retreat in quiet trading as they remain tightly coupled with broader market trends.
China's biotech giants are pivoting to pet weight-loss drugs. Explore the $2.1 billion race involving Fosun Pharma and Huadong Medicine in the China pet obesity GLP-1 drugs 2026 market.